Ronald Koschny

Prof. Dr. Ronald Koschny


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2013 in BMC Cancer
Verified
Journal Article
Open access
PDF file
RKRonald Koschny
Ronald Koschny
SBSylvia Brost
Sylvia Brost
UHUlf Hinz
Ulf Hinz
JSJaromir Sykora
Jaromir Sykora
EBEmanuela M Batke
Emanuela M Batke
TGTom M Ganten
Tom M Ganten
Background: An imbalance between proliferation and apoptosis is one of the main features of carcinogenesis. TRAIL (TNF-related apoptosis-inducing ligand) induces apoptosis upon binding to the TRAIL death receptors, TRAIL receptor 1 (TRAIL-R1) and TRAIL-R2, whereas binding to TRAIL-R3 and TRAIL-R4 might promote cell survival and proliferation. The anti-tumor activity of TRAIL-R1 and TRAIL-R2 agonists is currently investigated in clinical trials. To gain further insight into the regulation of apoptosis in hepatocellular carcinoma (HCC), we investigated the TRAIL pathway and the regulators of apoptosis caspase-8, Bcl-xL and Mcl-1 in patients with HCC regarding patient survival.Methods: We analyzed 157 hepatocellular carcinoma patients who underwent partial liver resection or orthotopic liver transplantation and healthy control liver tissue using immunohistochemistry on tissue microarrays for the expression of TRAIL-R1 to TRAIL-R4, caspase-8, Bcl-xL and Mcl-1. Immunohistochemical data were evaluated for potential associations with clinico-pathological parameters and survival.Results: Whereas TRAIL-R1 was downregulated in HCC in comparison to normal liver tissue, TRAIL-R2 and –R4 were upregulated in HCC, especially in G2 and G3 tumors. TRAIL-R1 downregulation and upregulation of TRAIL-R2 and TRAIL-R4 correlated with tumor dedifferentiation (G2/G3). TRAIL-R3, Bcl-xL and Mcl-1 showed no differential expression in tumor tissue compared to normal tissue. The expression levels of TRAIL receptors did not correlate with patient survival after partial hepatectomy. Interestingly, in tumor tissue, but not in normal hepatocytes, caspase-8 showed a strong nuclear staining. Low cytosolic and high nuclear staining intensity of caspase-8 significantly correlated with impaired survival after partial hepatectomy, which, for cytosolic caspase-8, was independent from tumor grade.Conclusions: Assessment of TRAIL-receptor expression patterns may have therapeutic implications for the use of TRAIL receptor agonists in HCC therapy. Tumor-specific nuclear localisation of caspase-8 in HCC suggests an apoptosis-independent function of caspase-8 and correlates with patient survival.

1 December 2017 in The American Journal of Emergency Medicine
Verified
Journal Article
Closed access
MFMina Farag
Mina Farag
DBDominika Badowski
Dominika Badowski
RKRonald Koschny
Ronald Koschny
GSGisela Skopp
Gisela Skopp
ABAndreas Brcic
Andreas Brcic
GSGabor B. Szabo
Gabor B. Szabo

27 October 2007 in European Journal of Pharmacology
Verified
Journal Article
Open access
DTDierk Thomas
Dierk Thomas
RBRamona Bloehs
Ramona Bloehs
RKRonald Koschny
Ronald Koschny
EFEckhard Ficker
Eckhard Ficker
JSJaromir Sykora
Jaromir Sykora
CKChristoph A. Karle
Christoph A. Karle
The antihypertensive drug doxazosin has been associated with an increased risk for congestive heart failure and cardiomyocyte apoptosis. Human ether-a-go-go-related gene (hERG) K+ channels, previously shown to be blocked by doxazosin at therapeutically relevant concentrations, represent plasma membrane receptors for the antihypertensive drug. To elucidate the molecular basis for doxazosin-associated pro-apoptotic effects, cell death was studied in human embryonic kidney cells using three independent apoptosis assays. Doxazosin specifically induced apoptosis in hERG-expressing HEK cells, while untransfected control groups were insensitive to treatment with the antihypertensive agent. An unexpected biological mechanism has emerged: binding of doxazosin to its novel membrane receptor, hERG, triggers apoptosis, possibly representing a broader pathophysiological mechanism in drug-induced heart failure.

1 November 2014 in Journal of Neuropathology & Experimental Neurology
Verified
Journal Article
Open access
PDF file
RKRonald Koschny
Ronald Koschny
CBChristina Boehm
Christina Boehm
MSMartin Ronald Sprick
Martin Ronald Sprick
THTobias L. Haas
Tobias L. Haas
HHHeidrun Holland
Heidrun Holland
TGTom M. Ganten
Tom M. Ganten
A meningioma is the most common primary intracranial tumor in adults. Here, we investigated the therapeutic potential of the tumor necrosis factor–rel

20 September 2009 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
RKRonald Koschny
Ronald Koschny
HHHeidrun Holland
Heidrun Holland
JSJaromir Sykora
Jaromir Sykora
HEHande Erdal
Hande Erdal
WKWolfgang Krupp
Wolfgang Krupp
TGTom M. Ganten
Tom M. Ganten

14 February 2019 in Oncology Letters
Verified
Journal Article
Open access
PDF file
EBEmanuel Buck
Emanuel Buck
MSMartin Sprick
Martin Sprick
MGMatthias M. Gaida
Matthias M. Gaida
CGCarsten Grüllich
Carsten Grüllich
TWTim Frederik Weber
Tim Frederik Weber
RKRonald Koschny
Ronald Koschny
Recently, a tumor‑autonomous cytochrome P450 (CYP)‑3A5‑mediated resistance to cancer therapy has been demonstrated in pancreatic ductal adenocarcinoma. Expression of CYP3A5, which is involved in the degradation of irinotecan, has also been reported in colorectal cancer (CRC). The aim of the present study was to analyze CYP3A5 expression in the normal colon, colon adenoma, CRC and normal tissues, as well as to examine whether CYP3A5 expression in CRC has an impact on tumor response to irinotecan treatment. Immunohistochemistry was used to assess 85 tissue samples from 65 patients with CRC, along with 15 samples of normal colon and 45 samples of colon adenoma (including tubular, tubulovillous, and sessile serrated adenomas), and a tissue microarray (TMA) comprised of 26 different normal tissue types. Expression of CYP3A5 was evaluated with a semi‑quantitative score. Tumor response to irinotecan therapy was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guidelines. In normal tissues, CYP3A5 was expressed in epithelial cells of the colon, gallbladder, kidney, liver, small intestine, stomach, thyroid gland and tonsil, as well as in nerves. Expression in colon mucosa was heterogeneous, with only weak staining in the minority of specimens. CYP3A5 exhibited markedly higher expression in adenomas compared with normal colon tissues. A statistically significant inverse correlation was identified between CYP3A5 expression in CRC tissues and tumor response to irinotecan therapy. Irinotecan treatment itself did not alter CYP3A5 expression in CRC tissues. As CYP3A5 is involved in the degradation of irinotecan, the significantly higher intratumoral expression of CYP3A5 in patients with CRC who do not respond to irinotecan‑based chemotherapy may indicate a causal role of CYP3A5 in tumor resistance.